



VILIN BIO MED LIMITED
An ISO 9001-2008 & GMP certified Company

December 14, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Symbol- VILINBIO

Sub: Submission of Revised Outcome of the Board Meeting held on November 10, 2023 as per NSE/CML/2018/02 dated January 16, 2018

Ref: (i) Outcome of the Board Meeting published on November 10, 2023

(ii) Intimation under Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, November 10, 2023, has inter-alia, considered and approved the unaudited Standalone Financial Results along with the Limited Review Report for the Half Year ended September 30, 2023 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) which has been duly reviewed and recommended by the Audit Committee of the Company.

A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. PPKG & Co., Chartered Accountants, is attached herewith.

The Financial Results are also hosted on the website of the company at www.vilinbiomed.co.in and National Stock Exchange of India Limited at www.nseindia.com

The Board Meeting commenced at 11:30 A.M. and concluded at 12:25 P.M.

We request you to kindly take the above information on record.

Thanking You

Yours sincerely

For **Vilin Bio Med Limited**

Viswa Prasad Sadhanala
Managing Director

Encl: as above

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: U24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED
An ISO 9001-2008 & GMP certified Company

VILIN BIO MED LIMITED

Registered Office : Sy.No.115/GF/J Haanumanji Colony, Brig Syeed Road, Bowenpally, Hyderabad - 500003

CIN : U24230TG2005PLC046689

Statement of Unaudited Financial Results for the Half Year ended September 30, 2023

(RS. IN LAKHS)

S.No.	Particulars	Half Year ended			Year Ended	
		30.09.2023 (Unaudited)	31.03.2023 (Audited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)	31.03.2022 (Audited)
	Income					
I	Revenue from operations	764.57	821.49	409.81	1,231.30	1,121.49
II	Other income	10.81	2.44	-	2.44	0.42
	Total Revenue (I+II)	775.38	823.93	409.81	1,233.74	1,121.91
	Expenses					
	Cost of materials consumed	483.04	478.75	230.78	709.53	887.67
	Change of Inventory	-	(2.92)	10.50	7.58	(0.88)
	Employee benefits expense	35.65	42.06	35.68	77.74	99.91
	Finance costs	37.76	32.90	31.95	64.84	50.61
	Depreciation and amortization expense	7.62	8.38	8.38	16.77	21.94
	Other expenses	106.99	156.76	22.36	179.12	58.19
	Total Expenses (III)	671.06	715.93	339.65	1,055.58	1,117.44
III	Profit before Exceptional and extraordinary items and tax (III-IV)	104.32	108.00	70.16	178.16	4.47
IV	Exceptional Items					
VII	Profit before extraordinary items and tax (V-VI)	104.32	108.00	70.16	178.16	4.47
VIII	Extraordinary items					
III	Profit / (Loss) before tax (VII-VIII)	104.32	108.00	70.16	178.16	4.47
IV	Tax expense:					
	Current tax	27.12	35.29	17.54	52.83	1.00
	Deferred tax	0.29	3.34	(2.50)	0.84	0.11
	Total Tax Expenses	27.41	38.63	15.04	53.67	1.11
IX	Profit/(loss) for the period from continuing operations (VIII-IX)	76.91	69.37	55.12	124.49	3.36
	Profit/(loss) from discontinuing operations					
	Tax expense of discontinuing operations					
	Profit/(loss) from Discontinuing operations (B)					
	Profit/(loss) for the year	76.91	69.37	55.12	124.49	3.36
	Earnings per equity share:					
	(1) Basic & Diluted	0.55	0.70	1.67	1.25	0.10
	(2) Diluted	0.55	0.70	1.67	1.25	0.10

Notes to Accounts :

- The above unaudited standalone financial results of Vilin Bio Med Limited ("the Company") as reviewed by the Audit Committee and has been approved by the Board of Directors of the Company at their respective meeting held on November 10, 2023. The Statutory Auditors of the Company have carried out the limited review on standalone financial results and expressed an unmodified conclusion thereon.
- The Financial results has been prepared in accordance with the accounting standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised accounting practices and policies as applicable.
- The financial results and other financial information for the corresponding Half Year ended September 30, 2023 have not been subject to audit by the statutory auditor. However, the management has exercised necessary due diligence and ensure that the financial result for this period provide a true and fair review of the Company's affair.
- The Company's business activity falls within a single business segment i.e., manufacturing of pharmaceutical products. The company operated only in one geographical segment i.e., domestic segment.



Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: U24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

- 5 The Company has completed fresh issue of Equity shares by Initial Public Offer ("IPO") of Rs.1200.00 Lakhs of 40,00,000 equity shares of face value Rs. 10/- each at an issue price of Rs. 30/- per equity share. The equity shares of the Company were listed on National Stock Exchange of India Ltd ("NSE") Emerge Platform on June 30, 2023. The details of utilization of the net proceeds as mentioned below:

(RS. IN LAKHS)

Particulars	As per the prospectus	Utilised till 30.09.2023	Balance
Requirements	850.00	547.00	303.00
General Corporate Purpose	250.00	40.00	210.00
Public Issue Expenses	100.00	97.00	3.00
Total	1200.00	684.00	516.00


* The Un-utilised amount of Rs. 516.00 lakhs is maintained in the Bank Account with Scheduled Commercial Bank.

- 6 Previous period's / year's figures have been re-grouped / re-arranged wherever necessary to correspond with the Current year's Classification / Disclosures.

Date : November 10, 2023

Place : Hyderabad

By the order of the Board
for VILIN BIO MED LIMITED



Viswa Prasad Sadhanala
Viswa Prasad Sadhanala
Managing Director
(DIN : 08068933)

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad - 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: U24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACC1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

VILIN BIO MED LIMITED

Registered Office : Sy.No.115/GF/J Hanumanji Colony, Brig Syeed Road, Bowenpally, Hyderabad - 500003


CIN : U24230TG2005PLC046689

Statement of Unaudited Financial Results for the half year ended September 30, 2023

		(RS. IN LAKHS)		
	Particulars	30/09/2023 (Unaudited)	31/03/2023 (Audited)	31/03/2022 (Audited)
I.	EQUITY AND LIABILITIES			
	1 Shareholders' funds			
	(a) Share capital	1,395.00	995.00	330.00
	(b) Reserves and surplus	949.67	72.76	409.61
	Total Shareholders fund	2,344.67	1,067.76	739.61
	2 Non-current liabilities			
	(a) Long-term borrowings	25.25	43.12	73.40
	(b) Deferred tax liabilities (Net)	7.30	7.00	5.81
	(c) Other Long term liabilities			
	(d) Long-term provisions			
		32.55	50.12	79.21
	3 Current liabilities			
	(a) Short-term borrowings	527.17	450.00	456.56
	(b) Trade payables			
	(i) Total outstanding dues of micro enterprises and small enterpris			
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	81.71	118.94	64.12
	(c) Other current liabilities	28.39	28.69	13.83
	(d) Short-term provisions	79.95	52.83	2.50
		717.22	650.46	537.01
	Total Equity and Liabilities	3,094.44	1,768.34	1,355.83
II	ASSETS			
	1 Non-current assets			
	(a) Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment	143.5	151.15	164.96
	(ii) Intangible assets			
	(iii) Capital work-in-progress			
	(iv) Intangible assets under development			
	(b) Non-current investments			
	(c) Long-term loans and advances			
	(d) Deferred tax assets (net)			
	(e) Other non-current assets	288.43	288.80	
		431.96	439.95	164.96
	2 Current assets			
	(a) Inventories	243.75	87.88	228.38
	(b) Trade receivables	1127.22	987.38	778.65
	(c) Cash and cash equivalents	653.24	3.45	3.90
	(d) Short-term loans and advances	127.67	71.87	61.52
	(e) Other current assets	510.6	177.81	118.43
	Total Current Assets	2662.48	1328.39	1190.88
	TOTAL ASSETS	3094.44	1768.34	1355.83

Date : November 10, 2023

Place : Hyderabad



By the order of the Board
for VILIN BIO MED LIMITED

Viswa Prasad Sadhanala
Managing Director
(DIN : 08068933)

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad - 500009, Telangana.

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: U24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

Vilin Bio Med Limited

Registered office: Sy.No.115/GF/J Hanumanji Colony, Brig Sayeed Road, Bowempally,Hyderabad - 500003

CIN: U24230TG2005PLC046689


Cash Flow Statement for the Half Year ended September 30, 2023

(Rs. In Lakhs)

Particulars	As at Sep-30-2023	As at Mar-31-2023	As at Mar-31-2022
Cash Flow from Operating Activities			
Net Profit Before Tax and Extra-ordinary Items	104.32	178.16	4.47
Adjustment For			
Depreciation	7.62	16.76	21.94
Provision for Doubtful debts		-	
Operating Profit before working capital changes	111.94	194.93	26.41
Adjustment For working Capital Change			
Adjustment for Increase/Decrease in Inventories	(155.87)	140.50	(21.96)
Adjustment for Increase/Decrease in Trade Receivables	(139.84)	(208.74)	(14.13)
Adjustment for Increase/Decrease in Short term Loans and Advances	(55.80)	(10.36)	43.61
Adjustment for Increase/Decrease in Non Current Assets	0.37	(289.16)	
Adjustment for Increase/Decrease in Other Current Assets	(332.79)	(59.36)	3.10
Adjustment for Increase/Decrease in Trade Payables	(37.23)	54.82	(17.56)
Adjustment for Increase/Decrease in Other Current Liabilities	(0.30)	14.87	5.40
Adjustment for Provisions	27.13	50.33	(3.00)
Total Adjustment For Working Capital (B)	(582.39)	(112.18)	21.87
Less: Income Tax Paid / Provided	27.12	53.67	1.00
Net Cash Flow from (used in) operation before Extra-ordinary Items	(609.51)	(165.84)	20.87
Proceeds from Extra-ordinary Items			
Payment for Extra-ordinary Items			
Net Cash Flow from Operating Activities	(609.51)	(165.84)	20.87
Cash Flows from Investing Activities			
Proceeds from Fixed Assets	-	(2.95)	
Proceeds from Investment or Equity Instruments			
Purchase of Fixed Assets			
Purchase of Investments or Equity Instruments			
Interest Received			
Dividend Received			
Cash Receipt from Sale of Interest in Joint Venture			
Cash Payment to acquire Interest in Joint Venture			
Cash Flow from loosing Control of Subsidiaries			
Cash Payment for acquiring Control of Subsidiaries			
Proceeds from Government Grant			
Other Inflow / Outflow of Cash			
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	-	(2.95)	
Proceeds from Extra Ordinary Items			
Payment for Extra Ordinary Item			
Net Cash Flow from (Used in) in Investing Activities	-	(2.95)	
Cash Flows from Financial Activities			
Proceeds From Issuing Shares	400.00	204.00	
Proceeds from Issuing shares for security premium	800.00	-	
Proceeds From Issuing Shares			
Redemption of Debentures			
Proceeds from other Equity Instruments			
Proceeds from Short term Borrowing		(6.56)	6.56
Repayment of Long term Borrowing	59.30	(29.09)	(28.18)
Dividend Paid			
Interest Paid			
Income Tax Paid / Refund			
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	1,259.30	168.35	(21.62)
Proceeds from Extra-ordinary Items			
Payment for Extra-ordinary Items			
Net Cash Flow from (Used in) in Financial Activities		168.35	(21.62)
Net Increase (Decrease) in Cash and Cash Equivalents	649.79	(0.45)	(0.75)
Cash and Cash equivalents at beginning of period	3.45	3.90	4.65
Cash and Cash equivalents at end of period	653.24	3.45	3.90

Date : November 10, 2023

Place : Hyderabad



By the order of the Board
for VILIN BIO MED LIMITED

Viswa Prasad Sadhanala
Managing Director
(DIN : 08068933)

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad - 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: U24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To
The Board of Directors
Vilin Bio Med Limited
Sy. 115/GF/J, Hanumanji Colony,
Brig Sayeed Road, Bowenpally
Secunderabad- 500003, Telangana

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Vilin Bio Med Limited (the "Company") for the Half-Year ended September 30, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement principles laid down in the Accounting Standard – 25 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other Accounting Principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A Review of the Interim Financial Information consists of making inquiries, primarily of the persons responsible for financial and accounting matters and applying Analytical and other Review Procedures. A Review is substantially less in scope than an Audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit Opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying

Statement, prepared in accordance with the applicable Accounting Standards and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & Co

Chartered Accountants

ICAI Firm Registration No. 0096558

Girdhari Lal Toshniwal



Girdhari Lal Toshniwal

Partner

Membership No. 205140

Date: 10/11/2023

Place: Hyderabad

UDIN: 23205140BGUNPZ3905.